In the phase III ATTLAS trial, for patients with NSCLC harboring EGFR mutations or ALK rearrangements, the combination of atezolizumab and bevacizumab with chemotherapy (ABCP) showed significantly higher objective response rates (69.5% vs. 41.9%, P < 0.001) and median PFS (8.48 vs 5.62 months, P = 0.004) compared to the chemotherapy (PC) arm. Here, ALK is linked to non-small cell lung carcinoma.